Janney Weighs in on Acceleron Pharma
Janney Capital has weighed in on biotech company Acceleron Pharma and what its outlook stands to be for the future.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 231
Mannkind Sinks on Afrezza License Termination
MannKind Corp. (NASDAQ: MNKD) is one of the most traded biotech companies on the market, and one of the most shorted as well. In Tuesday’s session the stock took a big downturn after the…
Akebia Plans to Raise Capital in Most Recent Proposed Offering
Akebia Therapeutics plans on raising capital, according to its most recent proposed public offering.
Bavarian Nordic Files for IPO
Bavarian Nordic has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Top Biotech Stock Favorites to Buy With Up to 100% Upside Potential
Like others on Wall Street, the analysts at the specialty biotech and health care boutique firm Leerink see 2016 as a year with some uncertainty.
4 Top FDA Decisions Expected in Q1
24/7 Wall St. has collected four companies big FDA decisions coming up in the first quarter of 2016 and added some color.
Sancilio Pharmaceuticals Files for IPO
Sancilio Pharmaceuticals has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Fitch Ratings Weighs In on the ACA
Fitch commented on the omnibus spending bill signed into law on December 18 that provides U.S. health insurers with a short-term reprieve by delaying the levy of three key Affordable Care Act (ACA) corporate…
KaloBios Files for Bankruptcy
KaloBios Pharmaceuticals filed for Chapter 11 bankruptcy on Tuesday morning, over a week after former CEO Martin Shkreli was arrested by the FBI for securities fraud.
Can NeuroMetrix Turn Itself Around?
NeuroMetrix might be turning itself around with the launch of its system for detecting diabetic neuropathy.
RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016
These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current trading levels.
Valeant CEO Takes Temporary Leave on Health Scare
Valeant Pharmaceuticals watched its shares move lower in Monday’s trading session on a health scare from one of its top executives.
Is There Any Hope for Chimerix?
Chimerix absolutely led the bears in Monday’s trading session on less-than-favorable results from a late-stage trial.
AnaptysBio Looking for More Funding in IPO
AnaptysBio has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Merrill Lynch Has 4 Large Cap Pharmaceutical Dividend Stocks for 2016
These companies all provide drugs and medical devices that help hundreds of thousands of people daily lead a better life. They make good sense for conservative portfolios looking for income and growth next year.